Upstream Bio UPB
NASDAQ UPB
$6.09 +0.01 (+0.18%)
As of: Sep 4, 2026 · 3:13 PM EDT

Upstream Bio (UPB) Other Non Operating Income (2023 - 2026)

Analysis

Upstream Bio (UPB) Other Non Operating Income (2023 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.58 Bn 130.73 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.33 Bn 77.33 Bn 3.93 Bn
3 Argenx Se 63.43 Bn 58.24 Bn 1.37 Bn
4 Moderna 57.84 Bn 52.70 Bn 52.00 Mn
5 Revolution Medicines 44.01 Bn 44.01 Bn -
6 BeOne Medicines 39.93 Bn 34.83 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.47 Bn 32.16 Bn 992.69 Mn
8 Royalty Pharma 28.39 Bn 27.56 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Upstream Bio 333.96 Mn 333.96 Mn -3.29 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 7,000.00
Mar 31, 2026 -30,000.00
Dec 31, 2025 54,000.00
Sep 30, 2025 -19,000.00
Jun 30, 2025 -50,000.00
Sep 30, 2024 -3,000.00
Jun 30, 2024 -15,000.00
Mar 31, 2024 -6,000.00
Dec 31, 2023 -7,000.00
Sep 30, 2023 -16,000.00